E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial.
作者信息
Bewersdorf Jan Philipp, Stahl Maximilian, Taylor Justin, Mi Xiaoli, Chandhok Namrata Sonia, Watts Justin, Derkach Andriy, Wysocki Mateusz, Lu Sydney X, Bourcier Jessie, Hogg Simon J, Rahman Jahan, Chaudhry Sana, Totiger Tulasigeri M, Abdel-Wahab Omar, Stein Eytan M
机构信息
Department of Medicine; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
出版信息
Leukemia. 2023 Dec;37(12):2512-2516. doi: 10.1038/s41375-023-02050-4. Epub 2023 Oct 9.
Abstract
摘要
Zotero 插件